A Novel Insulin Receptor-Binding Protein from Momordica charantia Enhances Glucose Uptake and Glucose Clearance in Vitro and in Vivo through Triggering Insulin Receptor Signaling Pathway

2014 ◽  
Vol 62 (36) ◽  
pp. 8952-8961 ◽  
Author(s):  
Hsin-Yi Lo ◽  
Tin-Yun Ho ◽  
Chia-Cheng Li ◽  
Jaw-Chyun Chen ◽  
Jau-Jin Liu ◽  
...  
Keyword(s):  
Insulin Receptor ◽  
Glucose Uptake ◽  
Signaling Pathway ◽  
Receptor Binding ◽  
Glucose Clearance ◽  
Insulin Receptor Signaling ◽  
Receptor Signaling Pathway ◽  
Receptor Binding Protein

Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase

2013 ◽  
Vol 41 (4) ◽  
pp. 1055-1060 ◽  
Author(s):  
Jason S. Kerr ◽  
Catherine H. Wilson
Keyword(s):  
Nuclear Receptor ◽  
Receptor Binding ◽  
Kinase Activity ◽  
Binding Protein ◽  
Kinase Domain ◽  
Present Review ◽  
Critical Components ◽  
Receptor Binding Protein

Pseudokinases are a class of kinases which are structurally designated as lacking kinase activity. Despite the lack of kinase domain sequence conservation, there is increasing evidence that a number of pseudokinases retain kinase activity and/or have critical cellular functions, casting aside previous notions that pseudokinases simply exist as redundant kinases. Moreover, a number of recent studies have implicated pseudokinases as critical components in cancer formation and progression. The present review discusses the interactions and potential functions that nuclear receptor-binding protein 1, a pseudokinase recently described to have a tumour-suppressive role in cancer, may play in cellular homoeostasis and protein regulation. The recent findings highlighted in the present review emphasize the requirement to fully determine the function of pseudokinases in vitro and in vivo, the understanding of which may ultimately uncover new directions for drug discovery.

Pharmacological Regulation of the Insulin Receptor Signaling Pathway Mimics Insulin Action in Cells Transduced with Viral Vectors

2004 ◽  
Vol 15 (11) ◽  
pp. 1101-1108 ◽  
Author(s):  
Gabriella Cotugno ◽  
Roy Pollock ◽  
Pietro Formisano ◽  
Katja Linher ◽  
Francesco Beguinot ◽  
...  
Keyword(s):  
Insulin Receptor ◽  
Signaling Pathway ◽  
Insulin Action ◽  
Viral Vectors ◽  
Receptor Signaling ◽  
Insulin Receptor Signaling ◽  
Receptor Signaling Pathway ◽  
Pharmacological Regulation ◽  
In Cells

scholarly journals Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity

PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88684 ◽  
Author(s):  
John A. Corbin ◽  
Vinay Bhaskar ◽  
Ira D. Goldfine ◽  
Daniel H. Bedinger ◽  
Angela Lau ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Glucose Metabolism ◽  
Insulin Receptor ◽  
Binding Affinity ◽  
Receptor Binding ◽  
Receptor Binding Affinity ◽  
Insulin Receptor Binding

Inhibiting α1-adrenergic Receptor Signaling Pathway Ameliorates Alzheimer’s Disease Type Pathologies and Behavioral Deficits in an AD Mouse Model

2021 ◽  
Author(s):  
Zhong-Yuan Yu ◽  
Xu Yi ◽  
Ye-Ran Wang ◽  
Gui-Hua Zeng ◽  
Cheng-Rong Tan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Signaling Pathway ◽  
Neuronal Loss ◽  
Behavioral Deficits ◽  
Bace1 Expression ◽  
Receptor Signaling Pathway ◽  
Gsk 3Β

Abstract Background The role of α1 adrenergic receptors (α1-ARs) signaling pathway in the pathogenesis of Alzheimer’s disease (AD) has rarely been investigated. Clarifying pathophysiological functions of α1-ARs in the AD brain is helpful for better understanding the pathogenesis and screening novel therapeutic target of AD. Methods This study included 2 arms of in vivo investigations: 1) 6-month-old female APPswe/PS1 mice were intravenously treated with AAV-PHP.eB-shRNA (ARs)-GFP or AAV-PHP.eB-GFP for 3 months. 2) 3-month-old female APPswe/PS1 mice were daily treated with 0.5 mg/kg terazosin or equal saline for 6 months. SH-SY5Y cell lines bearing human Amyloid precurssor protein were treated with terazosin or saline for investigating possible mechanisms. Results α1-ARs knockdown mice exhibited improved behavioral performances than control mice. α1-ARs knockdown mice had significantly lower brain amyloid burden, as reflected by soluble Aβ species, compact and total plaques, than control mice. The α1-ARs inhibitor terazosin substantially reduced Aβ deposition, attenuated downstream pathologies including Tau hyperphosphorylation, glial activation, neuronal loss, synaptic dysfunction, and rescued behavioral deficits of APPswe/PS1 mice. In vitro investigation demonstrated that α1-ARs inhibition down-regulated BACE1 expression, and promoted ser9 phosphorylation of GSK-3β, thus reduced Aβ production. Conclusions This study indicates that inhibition of α1-ARs signaling pathway might represent a promising therapeutic strategy for AD.

Sign in / Sign up

Export Citation Format

Share Document